The Effect of Heparin on the Bleeding Time

P. F Hjort; C. F Borchgrevink; O. H Iversen; H Stormorken

doi:10.1055/s-0038-1654522

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1960; 4(03): 389-399
DOI: 10.1055/s-0038-1654522

Originalarbeiten — Original Articles — Travaux Originaux

Schattauer GmbH

The Effect of Heparin on the Bleeding Time

P. F Hjort

¹Universitetets Institutt for Tromboseforskning, Rikshospitalet, Oslo. Universitetets Institutt for Generell og Eksperimentell Patologi, Rikshospitalet, Oslo. Fysiologisk Institutt, Veterinærhöyskolen, Oslo, Norway

,

C. F Borchgrevink

¹Universitetets Institutt for Tromboseforskning, Rikshospitalet, Oslo. Universitetets Institutt for Generell og Eksperimentell Patologi, Rikshospitalet, Oslo. Fysiologisk Institutt, Veterinærhöyskolen, Oslo, Norway

,

O. H Iversen

¹Universitetets Institutt for Tromboseforskning, Rikshospitalet, Oslo. Universitetets Institutt for Generell og Eksperimentell Patologi, Rikshospitalet, Oslo. Fysiologisk Institutt, Veterinærhöyskolen, Oslo, Norway

,

H Stormorken

¹Universitetets Institutt for Tromboseforskning, Rikshospitalet, Oslo. Universitetets Institutt for Generell og Eksperimentell Patologi, Rikshospitalet, Oslo. Fysiologisk Institutt, Veterinærhöyskolen, Oslo, Norway

› Author Affiliations

Abstract

Summary and Conclusions

1. Moderate doses of heparin often prolonged the bleeding time in men, rats and mice. The bleeding was wavelike, and a sensitive method was necessary to demonstrate the prolongation.

2. Large doses gave a prolonged bleeding time, and the bleeding was often profuse and continuous.

3. Heparin did not produce thrombocytopenia. Moderate doses probably prevent viscous metamorphosis and fibrin formation, resulting in large but inefficient platelet plugs. Large doses may also interfere with the aggregation of platelets, preventing the formation of platelet plugs.

Full Text

References

References
(1) Apitz K. Die Bedeutung der Gerinnung und Thrombose für die Blutstillung. Virchows Arch. path. Anat. 308: 540-614 1942;
(2) Best C. H, Campbell C, Maclean D. L. Heparin and the formation of white thrombi. J. Physiol. (Lond.) 92: 20-31 1938;
(3) Bergsagel D. E. Viscous metamorphosis of platelets: morphological platelet changes induced by an intermediate product of blood thromboplastin formation. Brit. J. Haemat. 2: 130-138 1956;
(4) Berman H. J, Fullon G. P, Lutz B. R, Pierce D. L. Susceptibility to thrombosis in normal young, aging, cortisone-treated, heparinized and X-irradiated hamsters as tested by topical application of thrombin. Blood 10: 831-840 1955;
(5) Borchgrevink C. F, Waaler B. A. The secondary bleeding time. Acta med. scand. 162: 361-374 1958;
(6) Bounameaux Y. Action de la thrombine et de la reptilase sur la métamorphose visqueuse des plaquettes de diverses espèces animales. Rev. franç. Ét. clin. biol. 4: 54-55 1959;
(7) Brecher G, Cronkite E. P. Morphology and enumeration of human blood platelets. J. appl. Physiol. 3: 365-377 1950;
(8) Cauwenberge H. van, Jaques L. B. Effect of dicumarol on bleeding time. Proc. Soc. exp. Biol. (N. Y.) 98: 599-602 1958;
(9) Copley A. L, Lalich J. J. The experimental production of a hemophilia-like condition in heparinized mice. Amer. J. Physiol. 135: 547-556 1942; a
(10) Copley A. L, Lalich J. J. Bleeding time, lymph time, and clot resistance in man. J. clin. Invest. 21: 145-152 1942; a
(11) Copley A. L, Robb T. P. Studies on platelets. III. The effect of heparin in vivo on the platelet count in mice and dogs. Amer. J. clin. Path. 12: 563-570 1942;
(12) Correll J. T, Lyth L. F, Long S, Vanderpoel J. C. Some physiologic responses to 5-hydroxytryptamine creatinine sulfate. Amer. J. Physiol. 169: 537-544 1952;
(13) Fullon G. P, Akers R. P, Lutz B. R. White thromboembolism and vascular fragility in the hamster cheek pouch after anticoagulants. Blood 8: 140-152 1953;
(14) Ganes J. Nord. Med. 16: 2841 1942;
(15) Halse T. Methodischer Beitrag zur experimentellen Prüfung der Blutungszeit. Klin. Wschr. 30: 693-694 1952;
(16) Hedenius P. Further experiences with heparinizing the donor in blood transfusions. Lancet 2: 1186-1188 1937;
(17) Heim W. Die indirekte Bluttransfusion mit „Vetren“. Münch. med. wschr. 85: 1157-1160 1938;
(18) Hjort P, Stormorken H. A study of the in vitro and in vivo effects of a synthetic heparin-like anticoagulant: dextran sulphate. Scand. J. clin. Lab. Invest. 9 (Suppl. 29) 1-86 1957;
(19) Hugues J. Contribution a l’étude des facteurs vasculaires et sanguines dans l'hémostase spontanée. Thesis. Liège: 1953: 1-151.
(20) Hugues J. Metamorphose visqueuse des plaquettes et formation du clou hémostatique. Thromb. Diath. haem. 3: 34-44 1959;
(21) Jores A, Detzel A. Heparin und seine praktische Anwendung. Klin. Wschr 19: 641-647 1940;
(22) Lalich J. J, Copley A. L. Clot resistance in mice and the mechanism of hemostasis. Arch. Surg. 46: 224-237 1943;
(23) Lalich J. J, Lalich M. H, Copley A. L. Bleeding time in mice following the administration of 3,3’-methylene-bis-(4-hydroxycoumarin). Surgery 13: 316-321 1943;
(24) Lewalle J, Bounameaux Y, Roskam J. Étude clinique “in vivo“ de la résistance du clou hémostatique chez l’homme. Thromb. Diath. haem. 3: 165-176 1959;
(25) Lindgren S, Wilander O. The use of heparin in vascular surgery. Acta med. scand 107: 148-160 1941;
(26) Macfarlane R. G. The mechanism of hemostasis. Quart. J. Med. 10: 129 1941;
(27) Quick A. J, Shanberge J. N, Stefanini M. The effect of heparin on platelets in vivo. J. Lab. clin. Med. 33: 1424-1430 1948;
(28) Roskam J. Mécanisme de la prévention et du traitement des thromboses par l’héparine. Arch. int. Pharmacodyn. 68: 66-80 1942;
(29) Sappington S. W. The use of heparin in blood transfusions. J. Amer. med Ass. 113: 22-25 1939;
(30) Shionoya T. Studies in experimental extracorporeal thrombosis. III. Effects of certain anticoagulants (heparin and hirudin) on extracorporeal thrombosis and on the mechanism of thrombus formation. J. exp. Med. 46: 19-26 1927;
(31) Sköld E. Heparin bei Blutttransfusionen. Acta med. scand. 88: 450-454 1936;
(32) Waaler B. A. Contact activation in the intrinsic blood clotting system. Scand. J. clin. Lab. Invest. 11 (Suppl. 37) 1-133 1959;
(33) Zucker H. D. Platelet thrombosis in human hemostasis. Blood 4: 631-645 1949;
(34) Zucker M. B. Platelet agglutination and vasoconstriction as factors in spontaneous hemostasis in normal, thrombocytopenic, heparinized and hypoprothrombinemie rats. Amer. J. Physiol. 148: 275-288 1947;
(35) Zucker M. B, Borrelli J. Viscous metamorphosis, clot retraction and other morphologic alterations of blood platelets. J. appl. Physiol. 14: 575-580 1959;